- Home
- PALI vs TMCI Comparison
PALI vs TMCI Comparison
Compare PALI & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PALI | TMCI |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.2M | 292.0M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PALI | TMCI |
|---|---|---|
| Price | $1.16 | $4.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 5 |
| Target Price | ★ $9.80 | $5.50 |
| AVG Volume (30 Days) | ★ 2.8M | 202.1K |
| Earning Date | 11-13-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.06 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $260,000.00 | ★ $212,690,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1500.39 | 1.59 |
| 52 Week Low | $1.10 | $1.17 |
| 52 Week High | $2.86 | $6.65 |
Technical Indicators
Market Signals| Indicator | PALI | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 30.13 | 57.20 |
| Support Level | N/A | $4.31 |
| Resistance Level | $2.19 | $4.67 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 13.57 | 58.25 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.